PMID: 9549650Apr 29, 1998Paper

Effect of troglitazone on steady-state pharmacokinetics of digoxin

Journal of Clinical Pharmacology
C M LoiA J Sedman

Abstract

Twelve healthy subjects participated in a study to determine the effect of multiple doses of troglitazone on the steady-state pharmacokinetics of digoxin. Subjects received digoxin 0.25 mg orally once daily on days 1 through 20 and 400 mg of troglitazone orally once daily on days 11 through 20. Serial plasma samples and 24-hour urine samples collected before and after the doses on days 10 and 20 were analyzed for digoxin using a radioimmunoassay method. Eleven subjects completed the study. Administration of multiple oral doses of digoxin and troglitazone was well tolerated. Mean values for maximum concentration (Cmax), time to Cmax (tmax), and area under the concentration-time curve from 0 to 24 hours (AUC0-24) of digoxin on day 10 were similar to those on day 20. Mean day 10 digoxin values for minimum concentration (Cmin), apparent oral clearance (Cl/F), total urinary excretion from 0 to 24 hours (Ae0-24), and renal clearance (Clr) were also similar to corresponding values on day 20. Thus, concomitant administration of multiple-dose troglitazone does not alter the steady-state pharmacokinetics of digoxin.

References

May 1, 1978·Diabetes Care·H E Lebovitz, M N Feinglos
Nov 1, 1978·Journal of Pharmaceutical Sciences·K S AlbertJ G Wagner
Nov 4, 1976·The New England Journal of Medicine·D D Brown, R P Juhl
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Oct 1, 1990·Metabolism: Clinical and Experimental·T P CiaraldiK A Heidenreich
Oct 1, 1988·Clinical Pharmacokinetics·S M Rodin, B F Johnson
Mar 1, 1980·Clinical Pharmacokinetics·J K Aronson
Jan 1, 1981·International Journal of Cardiology·J T Bigger
Jul 1, 1982·Journal of Clinical Pharmacology·K W HallA R DiSanto
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
Jun 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·H Boxenbaum
Feb 1, 1981·British Journal of Clinical Pharmacology·K Schenck-Gustafsson, R Dahlqvist
Sep 1, 1981·Clinical Pharmacology and Therapeutics·K E PedersenF Nielsen-Kudsk
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
Mar 20, 1998·Journal of Clinical Pharmacology·C M LoiJ R Koup

❮ Previous
Next ❯

Citations

Apr 27, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Harma EllensCaroline A Lee
Oct 26, 2002·Chemico-biological Interactions·Saileta PrabhuAlbert P Li
Feb 28, 2001·Diabetes, Obesity & Metabolism·C A Reasner
Mar 19, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jasminder SahiMichael W Sinz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.